Assoc. prof. Maria Jordanova Dimitrova graduated from the Faculty of Pharmacy of the Medical University-Sofia in 2008. Since 2013 she has been a senior assistant and since 2017 an associate professor at the Department of Organization and Economics of Pharmacy. She defended her PhD thesis in “Pharmacoeconomics and Pharmaceutical Regulation” on “Pharmacoeconomic analysis of highly active antiretroviral therapy for the treatment of HIV/AIDS in Bulgaria”. She holds a degree in “Organization and Economics of Pharmacy and Distribution Practice” and “Clinical Pharmacy”, acquired at MU-Sofia and master degree in health economics and pharmacoeconomics from Barcelona School of Management, Universitat Pompeu Fabra.
Currently he holds the position of Associate Professor at the Department of Pharmacy Organization and Economics. He participates in the training of “Medical Devices”, “Social Pharmacy and Pharmaceutical Legislation” “Pharmacoeconomics”, “Pharmaceutical Care”, “Quality Management in Pharmacy”, “Pharmacoepidemiology”. “Pharmaceutical Business” and “Pharmaceutical Marketing Management”, “Regulation of Clinical Trials”, “Pharmaceutical System”, “Introduction to Pharmacoeconomics and Health Economics” and “HI and PHI Assessments”. Her research work and contributions are in the area of pharmaceutical legislation and pharmacoeconomics.
She is author in 74 publications, 4 textbooks, 1 monograph with 308 citations in indexed journals in Elsevier’s Scopus and Google scholar. Maria Dimitrova is expert in health economics, pharmacoeconomics and pharmaceutical legislation and drug safety.
She is participant in 2 national research projects funded by the MU-Sofia and the National Research Fund and in 3 international research projects funded by the European Union’s Horizon 2020, COST (European Cooperation in Science and Technology), Erasmus +
Reviewer for scientific journals – Journal of Medical Economics, European Journal of Hospital Pharmacy, Pharmacia, and Associated Editor for Frontiers in Pharmacology.
Member of expert groups at the National Council on Prices and Reimbursement of Medicines.
Member of professional organizations and associations – Bulgarian Association of Pharmacoeconomics, Bulgarian Association of Drug Information, Bulgarian Pharmaceutical Union, Bulgarian Scientific Society of Pharmacy, ISPOR.
Link to professional and scientific pages:
- Maria Dimitrova, Petya Milushewa, Elina Petrova, Desislava Mihaylova, Nezabravka Tzvetanova, Guenka Petrova. TNBC in Bulgaria: epidemiological data and treatment patterns on real world evidence and patient registries. Biotechnology and biotechnological equipment 2021; IF (2020) = 1.632
- Maria Kamusheva, Konstantin Tachkov, Maria Dimitrova, Zornitsa Mitkova, Gema Garcia-Saez, María Elena Hernando, Wim Goettsch and Guenka Petrova. A systematic review of collective evidences investigating the effect of diabetes monitoring systems and their application in health care. Frontiers in Endocrinology-Clinical Diabetes. 2021. IF = 3.644
- Luka Vončina, Tea Strbad, Jurij Fürst, Maria Dimitrova, Maria Kamusheva, Megi Vila, Ileana Mardare, Kristina Hristova, Andras Harsanyi, Dragana Atanasijević, Igor Banović, Ana Bobinac. Pricing and reimbursement of patent protected medicines: challenges and lessons from South-eastern Europe. Applied Health Economics and Health Policy. 2021. https://link.springer.com/article/10.1007%2Fs40258-021-00678-w IF (2020) = 2.561
- Dimitrova, M., Tachkov, K., Petrova, G. Economic consequences of the implementation of national screening program for chronic HCV infection. 2020. Expert Review of Pharmacoeconomics and Outcomes Research DOI.1080/14737167.2019.1666000 IF (2020) = 2.032
- M. Rotar, A. Preda, O.Lobolova, V. Benkovic, S. Zawodnik, L. Gulacsi, M. Niewada, I. Boncz, G. Petrova, M. Dimitrova et al. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European Countires. Health Policy 2018; doi https://doi.org/10.1016/j.healthpol.2018.01.006 IF (2018) = 2.119
- European Union’s Horizon 2020 research and innovation programme under grant agreement No 825162: “HTx: Next Generation Health Technology Assessment to support patient-centered, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe” (H2020-825162, 2019-2023) https://www.htx-h2020.eu/about-htx-project/;
- COST Action CA19132 “ENABLE,” supported by the COST (European Cooperation in Science and Technology) https://enableadherence.eu/
- COST Action CA18218, European burden-eu of disease network https://www.burden-eu.net/;
- Erasmus+ KA2 Strategic Partnership Project on Joint Curriculum Development in Health Technology Assessment (HTA), финансиран от European Commission ERASMUS.